Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights

Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis and network meta-analysis of randomized trials with 94,283 participants

(2019) Henock G Yebyo et al.   AMERICAN HEART JOURNAL

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol

(2019) Scott M. Grundy et al.   CIRCULATION

Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events

(2019) Jane Armitage et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register

(2018) S.E. Humphries et al.   ATHEROSCLEROSIS

Next-generation sequencing technologies and their application to the study and control of bacterial infections

(2018) J. Besser et al.   CLINICAL MICROBIOLOGY AND INFECTION

Inclisiran for the treatment of dyslipidemia

(2018) Toshiyuki Nishikido et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey

(2018) Pompilio Faggiano et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering

(2018) Eliano P. Navarese et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Mendelian randomization: Its impact on cardiovascular disease

(2018) Masa-aki Kawashiri et al.   Journal of Cardiology

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1

(2018) Omar Abdel-Razek et al.   Journal of Clinical Lipidology

Severe xanthomatosis in heterozygous familial hypercholesterolemia

(2018) Sumayah Aljenedil et al.   Journal of Clinical Lipidology

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

(2018) Tymon Pol et al.   Journal of the American Heart Association

Clinical Genetic Testing for Familial Hypercholesterolemia

(2018) Amy C. Sturm et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

(2018) Lawrence A. Leiter et al.   DIABETES CARE

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary

(2018) Scott M. Grundy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

PCSK9 inhibitors: clinical evidence and implementation

(2018) Marc S. Sabatine   Nature Reviews Cardiology

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol

(2017) Gilbert R Thompson et al.   EUROPEAN HEART JOURNAL

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials

(2017) Konstantinos C Koskinas et al.   EUROPEAN HEART JOURNAL

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Recent advances in genetic testing for familial hypercholesterolemia

(2017) Michael A. Iacocca et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia

(2017) Yu Kataoka et al.   Journal of Clinical Lipidology

Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease

(2017) Thomas R. Webb et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis

(2017) Chengfeng Qiu et al.   Lipids in Health and Disease

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipoprotein Lipase (LPL) Polymorphism and the Risk of Coronary Artery Disease: A Meta-Analysis

(2017) Li Xie et al.   International Journal of Environmental Research and Public Health

Targeting LDL Cholesterol: Beyond Absolute Goals Toward Personalized Risk

(2017) Morton Leibowitz et al.   Current Cardiology Reports

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin

(2017) Robert P. Giugliano et al.   JAMA Cardiology

Genetics of Dyslipidemia

(2016) Diego García-Giustiniani et al.   Arquivos Brasileiros de Cardiologia

Familial Hypercholesterolemia Phenotype in Chinese Patients Undergoing Coronary AngiographyHighlights

(2016) Jian-Jun Li et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The High-Density Lipoprotein PuzzleSignificance

(2016) Robert S. Rosenson   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Heterozygous Familial Hypercholesterolemia

(2016) Angela Onorato et al.   CIRCULATION

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions

(2016) Michael G. Silverman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia

(2016) Amit V. Khera et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease

(2016) Amit V. Khera et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association between Apolipoprotein C-III Gene Polymorphisms and Coronary Heart Disease: A Meta-analysis

(2016) Jing-Zhan Zhang et al.   Aging and Disease

Association of Apolipoprotein C3 Genetic Polymorphisms with the Risk of Ischemic Stroke in the Northern Chinese Han Population

(2016) Yanzhe Wang et al.   PLoS One

Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL–C levels in a latvian population

(2015) Ilze Radovica-Spalvina et al.   BMC Medical Genetics

Familial Hypercholesterolemia

(2015) Victoria Enchia Bouhairie et al.   CARDIOLOGY CLINICS

Targeted next-generation sequencing to diagnose disorders of HDL cholesterol

(2015) Singh N. Sadananda et al.   JOURNAL OF LIPID RESEARCH

The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis

(2015) Gaojun Cai et al.   Lipids in Health and Disease

Apolipoprotein C-III

(2015) Alison B. Kohan   Current Opinion in Endocrinology Diabetes and Obesity

Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing: a population-based study

(2014) Penny J Norsworthy et al.   BMC Medical Genetics

Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population-Modeling Approach

(2014) N Tsamandouras et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

(2014) L B Ramsey et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome

(2014) Barbara Sjouke et al.   EUROPEAN HEART JOURNAL

Apolipoprotein C3 genetic polymorphisms are associated with lipids and coronary artery disease in a Chinese population

(2014) FengHe Cui et al.   Lipids in Health and Disease

Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care

(2013) Marianne K. DeGorter et al.   Circulation-Cardiovascular Genetics

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia

(2013) Jana Vandrovcova et al.   GENETICS IN MEDICINE

Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study

(2013) Philippa J Talmud et al.   LANCET

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

(2012) Benjamin F Voight et al.   LANCET

Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT

(2011) Ian Tietjen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Type 1 Hyperlipoproteinemia and Recurrent Acute Pancreatitis due to Lipoprotein Lipase Antibody in a Young Girl with Sjögren's Syndrome

(2011) Ambika P. Ashraf et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort

(2011) Michel R. Hoenig et al.   Journal of Clinical Lipidology

Genetically Elevated Apolipoprotein A-I, High-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease

(2010) Christiane L. Haase et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?: Fig. 1.

(2010) Menno Vergeer et al.   JOURNAL OF LIPID RESEARCH

Biological, clinical and population relevance of 95 loci for blood lipids

(2010) Tanya M. Teslovich et al.   NATURE

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

(2010) D Wang et al.   PHARMACOGENOMICS JOURNAL

Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort

(2009) John F. Thompson et al.   Circulation-Cardiovascular Genetics

Association of Three Lipoprotein Lipase Polymorphisms with Coronary Artery Disease in Chinese and Asian Indians

(2009) Chew-Kiat Heng et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction

(2008) J. J. Regieli et al.   EUROPEAN HEART JOURNAL

Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease

(2008) Tuomo Nieminen et al.   PHARMACOGENOMICS

Familial lipoprotein lipase deficiency caused by known (G188E) and novel (W394X) LPL gene mutations

(2008) A J Hooper et al.   ANNALS OF CLINICAL BIOCHEMISTRY